173 related articles for article (PubMed ID: 33624150)
21. Re: The clinical impact of a combined gamma camera/CT imaging system on somatostatin receptor imaging of neuroendocrine tumours in receptor imaging.
Adesanya O
Clin Radiol; 2007 Jan; 62(1):92; author reply 93. PubMed ID: 17145272
[No Abstract] [Full Text] [Related]
22. SNM 2012 image of the year.
J Nucl Med; 2012 Oct; 53(10):23N. PubMed ID: 23028181
[No Abstract] [Full Text] [Related]
23. Neuroendocrine tumours in 2016: Defining rules for increasingly personalized treatments.
Falconi M; Partelli S
Nat Rev Clin Oncol; 2017 Feb; 14(2):80-82. PubMed ID: 27922042
[No Abstract] [Full Text] [Related]
24. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations.
Sundin A; Vullierme MP; Kaltsas G; Plöckinger U; ;
Neuroendocrinology; 2009; 90(2):167-83. PubMed ID: 19077417
[No Abstract] [Full Text] [Related]
25. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide.
Kwekkeboom DJ; Krenning EP; Scheidhauer K; Lewington V; Lebtahi R; Grossman A; Vitek P; Sundin A; Plöckinger U; ;
Neuroendocrinology; 2009; 90(2):184-9. PubMed ID: 19713709
[No Abstract] [Full Text] [Related]
26. PET-Based Molecular Imaging in Designing Personalized Management Strategy in Gastroenteropancreatic Neuroendocrine Tumors.
Basu S; Ranade R; Ostwal V; Shrikhande SV
PET Clin; 2016 Jul; 11(3):233-41. PubMed ID: 27321028
[TBL] [Abstract][Full Text] [Related]
27. Bench-to-Bedside Theranostics in Nuclear Medicine.
Jokar N; Assadi M; Yordanova A; Ahmadzadehfar H
Curr Pharm Des; 2020; 26(31):3804-3811. PubMed ID: 32067609
[TBL] [Abstract][Full Text] [Related]
28. The SNMMI and EANM practice guideline for renal scintigraphy in adults.
Blaufox MD; De Palma D; Taylor A; Szabo Z; Prigent A; Samal M; Li Y; Santos A; Testanera G; Tulchinsky M
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2218-2228. PubMed ID: 30167801
[TBL] [Abstract][Full Text] [Related]
29. Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine.
Langbein T; Weber WA; Eiber M
J Nucl Med; 2019 Sep; 60(Suppl 2):13S-19S. PubMed ID: 31481583
[TBL] [Abstract][Full Text] [Related]
30. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: echocardiography.
Plöckinger U; Gustafsson B; Ivan D; Szpak W; Davar J; ;
Neuroendocrinology; 2009; 90(2):190-3. PubMed ID: 19713710
[No Abstract] [Full Text] [Related]
31. GEP-NETS update: functional localisation and scintigraphy in neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETs).
de Herder WW
Eur J Endocrinol; 2014 May; 170(5):R173-83. PubMed ID: 24723670
[TBL] [Abstract][Full Text] [Related]
32. Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms.
Waseem N; Aparici CM; Kunz PL
J Nucl Med; 2019 Jul; 60(7):882-891. PubMed ID: 30850504
[TBL] [Abstract][Full Text] [Related]
33. Developing a unified imaging approach for neuroendocrine tumours with the evolution of PET-CT with ⁶⁸Ga-labelled somatostatin analogues: could this be tailored according to specific clinical context and individual patient requirement?
Basu S
Nucl Med Commun; 2012 Oct; 33(10):1007-10. PubMed ID: 22850607
[No Abstract] [Full Text] [Related]
34. Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours.
Lykoudis PM; Partelli S; Muffatti F; Caplin M; Falconi M; Fusai GK;
Eur J Surg Oncol; 2019 Jan; 45(1):46-51. PubMed ID: 29126671
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours).
Kos-Kudła B; Blicharz-Dorniak J; Handkiewicz-Junak D; Jarząb B; Jarząb M; Kunikowska J; Kuśnierz K; Król R; Królicki L; Krzakowski M; Nasierowska-Guttmejer A; Nowakowska-Duława E; Patkowski W; Szawłowski AW; ;
Endokrynol Pol; 2013; 64(6):418-43. PubMed ID: 24431116
[TBL] [Abstract][Full Text] [Related]
36. Physiopathological Premises to Nuclear Medicine Imaging of Pancreatic Neuroendocrine Tumours.
Cuccurullo V; Di Stasio GD; Mansi L
Curr Radiopharm; 2019; 12(2):98-106. PubMed ID: 30727940
[TBL] [Abstract][Full Text] [Related]
37. [68Ga-DOTA-PET for neuroendocrine tumours].
Loimaala A; Mäenpää H; Lipponen T; Schildt J; Kämäräinen EL; Karhumäki L; Ahonen A
Duodecim; 2014; 130(19):1931-8. PubMed ID: 25558614
[TBL] [Abstract][Full Text] [Related]
38. Molecular Imaging in the Head and Neck: Diagnosis and Therapy.
Howard BA
Radiol Clin North Am; 2020 Nov; 58(6):1135-1146. PubMed ID: 33040853
[TBL] [Abstract][Full Text] [Related]
39. Molecular imaging for neuroendocrine tumours.
Antwi K; Nicolas G; Wild D; Christ E
Swiss Med Wkly; 2019 Feb; 149():w20017. PubMed ID: 30852831
[TBL] [Abstract][Full Text] [Related]
40. Nuclear Medicine Imaging of Neuroendocrine Tumors.
Brabander T; Kwekkeboom DJ; Feelders RA; Brouwers AH; Teunissen JJ
Front Horm Res; 2015; 44():73-87. PubMed ID: 26303705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
